¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell cycle restriction point"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® nerve cell ÇÑ±Û ½Å°æ¼¼Æ÷
¼³¸í   
  ½Å°æ¼¼Æ÷´Â ¿Ã¹Ù¸¥ ½Å°æÀü´ÞÀ» À§ÇÑ °¢ ºÎºÐº°·Î ³ª´µ¾îÁ® ÀÖ´Ù. ½Å°æ¼¼Æ÷¿¡¼­´Â ÀüÇØÁ®¿À´Â ÀÚ±ØÀ» Àü±âÀûÀΠ½ÅÈ£·Î ¹Ù²î¾î º¸³»°Å³ª ¹Þ°Ô µÈ´Ù. ÀÌ·± Àü±âÀûÀΠÇö»óÀº °¢ ½Å°æ¼¼Æ÷³»¿¡ Á¸ÀçÇϴ °¢ ÀÌ¿Âä³Î(ion channel: ionÀ̶õ ³ªÆ®·ý, Ä®·ý µîÀ» ÁöĪÇϴ ¸»µé·Î½á, À̵éÀÌ ¼¼Æ÷¸·¿¡ ÀÇÇØ ³ª´µ¾îÁú ¶§ »ý±â´Â Àü¾ÐÂ÷°¡ Àü±âÀû ÀÚ±ØÀ» ÀÏÀ¸Å°°í À¯ÁöÇϴµ¥ °áÁ¤ÀûÀΠ¿ªÇÒÀ» ÇÑ´Ù)µéÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ÀÌ·ç¾îÁö°Ô µÈ´Ù.
¿µ¹® glia cell ÇÑ±Û ¾Æ±³¼¼Æ÷
¼³¸í   
  ½Å°æ¼¼Æ÷ »çÀÌ¿¡¼­ ±×¹°±¸Á¶¸¦ ÀÌ·ç¸ç À̸¦ ÁöÁöÇϴ Á¶Á÷. ½Å°æ¾Æ±³¼¼Æ÷´Â ½Å°æ¸ð¼¼Æ÷¿Í °¥¶óÁø ¾Æ±³¸ð¼¼Æ÷°¡ ´Ù½Ã ¿©·¯ ÇüÅ·ΠºÐÈ­-¼ºÀåÇÑ °ÍÀÌ´Ù. ³ú½ÇÀ̳ª Ã´¼öÁ߽ɰüÀÇ º®À» µ¤°í ¿øÁÖ»ó ¶Ç´Â ÀÔ¹æÇüÀ̸ç, Ãʱ⿡´Â À¯¸®¸é¿¡ ¼¶¸ð°¡ ÀÖ´Ù. ´ëÇü¼¼Æ÷´Â º°³ú½Ç¸·¼¼Æ÷´Â ¾Æ±³¼¼Æ÷¶ó°í Çϸç, ½Å°æ¼¼Æ÷³ª ½Å°æ¼¶À¯ »çÀÌ¿¡ »êÀçÇÑ´Ù. ±× ¿Ü¿¡ Èñ¼Òµ¹±â¾Æ±³¼¼Æ÷µµ Æ÷ÇԵȴÙ.
¿µ¹® reserve cell ÇÑ±Û ¿¹ºñ¼¼Æ÷
¼³¸í   
  ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼­ À̹̠ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇϸ頸ŲãÁö´Â ±× ¹Ø¿¡ Àִ ¹ÌºÐÈ­¼¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ Àִ ÀÛÀº ¹ÌºÐÈ­ »óÇÇ ¼¼Æ÷.
¿µ¹® stem cell ÇÑ±Û Áٱ⼼Æ÷, °£¼¼Æ÷
¼³¸í   
  Àڱ⠺¹Á¦¸¦ ÇÏ¿© ÀÚ½ÅÀ» Á¸¼Ó½ÃŰ¸é¼­ ÇÑÆíÀ¸·Î´Â Áõ½Ä°ú ºÐÈ­¸¦ ÇÏ¿© »õ·Î¿î ¼¼Æ÷¸¦ Çü¼ºÇϴ ¼¼Æ÷·Î¼­ Á¶Ç÷Áٱ⼼Æ÷°¡ ´ëÇ¥ÀûÀÌ´Ù. Á¶Ç÷Áٱ⼼Æ÷´Â °ñ¼ö¿¡ Àִ ¼¼Æ÷·Î¼­ ¸ðµç Ç÷±¸¼¼Æ÷°¡ ¿©±â¿¡¼­ ºÐÈ­µÇ¾î ¹ß»ýÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Cori cycle
    ÄÚ¸®È¸·Î
  • cross bridge cycle
    ±³Â÷°áÇÕÁÖ±â
  • cycle
    1. ÁÖ±â 2. ¼øÈ¯ 3. ȸ·Î 4. °í¸® 5. Á֯ļö
  • cardiovascular cycle
    ½ÉÀåÇ÷°üÁÖ±â
  • duty cycle
    µ¿ÀÛºñÀ²
  • developmental cycle
    ¹ßÀ°ÁÖ±â
  • diurnal cycle
    ÀÏÀÏÁÖ±â
  • exoerythrocytic cycle
    ÀûÇ÷±¸¿Ü¹ßÀ°°í¸®
  • endogenous cycle
    ³»ÀÎÁÖ±â
  • epidemic cycle
    À¯Çà¼øÈ¯
  • erythrocytic cycle
    ÀûÇ÷±¸³»¹ßÀ°°í¸®
  • estrous cycle
    ¹ßÁ¤ÁÖ±â
  • free-living cycle
    ÀÚÀ¯»ýȰ°í¸®
  • glucose lactate cycle
    Æ÷µµ´çÁ¥»ê¿°È¸·Î
  • gonadotrophic cycle
    »ý½Ä»ùÀÚ±ØÁÖ±â, »ý½Ä¼±ÀÚ±ØÁÖ±â
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • near point
    ±ÙÁ¡
  • reference point
    ±âÁØÁ¡
  • saturation point
    Æ÷È­Á¡
  • tender point
    ¾ÐÅëÁ¡, ´©¸§ÅëÁ¡
  • sickle cell anemia
    ³´ÀûÇ÷±¸ºóÇ÷
  • cell
    ¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • beta cell
    º£Å¸¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cardiovascular cycle
    ½ÉÀåÇ÷°üÁÖ±â
  • citric acid cycle
    ±¸¿¬»êȸ·Î, ½ÃÆ®¸£»êȸ·Î
  • cross bridge cycle
    ±³Â÷°áÇÕÁÖ±â
  • cycle life
    »ýȰ»ç, »ýȰÁÖ±â
  • day-night cycle
    ³·¹ãÁÖ±â
  • developmental cycle
    ¹ßÀ°ÁÖ±â
  • diurnal cycle
    Àϰ£ÁÖ±â
  • duty cycle
    µ¿ÀÛºñÀ²
  • endogenous cycle
    ³»ÀμºÁÖ±â
  • epidemic cycle
    À¯Çà¼øÈ¯
  • erythrocytic cycle
    ÀûÇ÷±¸³»¹ßÀ°°í¸®
  • estrous cycle
    ¹ßÁ¤ÁÖ±â
  • exoerythrocytic cycle
    ÀûÇ÷±¸¿Ü¹ßÀ°°í¸®
  • free-living cycle
    ÀÚÀ¯»ýȰ°í¸®
  • glucose lactate cycle
    ±Û·çÄÚ¿À½º¶ôÆ®»êȸ·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • genesial cycle
    ¿©ÀÚ»ý½ÄÁÖ±â.
  • glucose lactate cycle
    ±Û·çÄÚ¿À½º¶ôÆ®»ê ȸ·Î.
  • gravitational cycle
    ÀÓ½ÅÁÖ±â
  • growth cycle
    Áõ½ÄÁÖ±â
  • hair cycle
    ¸ð¹ßÁÖ±â(Ù¾ ñÎÑ¢)
  • hydrogen cycle
    ¼ö¼Òȯ(¡­ü»), ¼ö¼Ò°í¸®.
  • infection cycle
    °¨¿°»ç, °¨¿°È¯
  • photochemical cycle
    ±¤È­Çаæ·Î(¡­ÌèÖØ).
  • pulse cycle
    ¸Æ¹ÚÁÖ±â(ØæÚÑñ²Ñ¢).
  • J point
    J Á¡(ïÇ)
  • NPA->near point of accommodation
    Á¶Àý±ÙÁ¡
  • NPC->near point of convergence
    ´«¸ðÀ½±ÙÁ¡, ÆøÁÖ±ÙÁ¡
  • Wilkerson point system
    ÀªÄ¿½¼Á¡¼öü°è
  • alveolar point =prosthion
    Ä¡Á¶Á¡(¡­ïÇ).
  • apex beat =point of maximum impulse
    ½É÷¹Úµ¿(ãýôÓÚÑÔÑ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • restriction enzymes
    Á¦ÇÑÈ¿¼Ò(ð¤ùÚý£áÈ)
  • restriction fragment length polymorphism
    Á¦ÇѼ¼Æí±æÀÌ´ÙÇü¼º(ð¤ùÚ¼¼Æí¡­Òýû¡à÷)
  • restriction fragment length polymorphism,in cystic fibrosis
    ³¶¼º¼¶À¯Áõ(ÀÇ)¡­(Ò¥àõàéë«ñø¡­)
  • restriction fragment length polymorphism analysis
    Á¦ÇÑÀý´Ü±æÀÌ´ÙÇüÁõºÐ¼®
  • restriction fragment length polymorphism=RFLP
    Á¦ÇÑÀýÆí±æÀ̴پ缺
  • restriction map
    Á¦ÇÑÈ¿¼ÒÁöµµ
  • restriction, H-2
    H-2 Â÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • restriction, Ia
    IaÂ÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • restriction, MHC
    MHCÂ÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • restriction, genetic
    À¯ÀüÀû »óÈ£ÀÛ¿ëÁ¦ÇÑ
  • sleep position restriction
    ¼ö¸éÀÚ¼¼Á¦ÇÑ
  • sleep restriction therapy
    ¼ö¸éÁ¦ÇÑ¿ä¹ý
  • cell cycle
    ¼¼Æ÷ÁÖ±â(¡­ñ²Ñ¢)
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell cycle
    ¼¼Æ÷ÁÖ±â
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
  • Secretory epithelial cell [Glandular cell]
    ºÐºñ»óÇǼ¼Æ÷ [»ù¼¼Æ÷]
    [¿¾ ¿ë¾î] ºÐºñ»óÇǼ¼Æ÷
  • Interstitial cell [Dark cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Interstitial cell [Leydig`s cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Bronchiolar cell [Clara cell]
    ¼¼±â°üÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐºñ¼¼Æ÷
  • Parafollicular cell [Calcitonin cell]
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Neurolemmal cell [Schwann`s cell]
    ½Å°æÁý¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æÃʼ¼Æ÷
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Striated muscle cell
    °¡·Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ⱦ¹®±Ù¼¼Æ÷
  • Sensory epithelial cell
    °¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • restriction polymorphism
    Á¦ÇÑ ´ÙÇü¼º(Òýúþàõ)
  • restriction site
    Á¦ÇÑ ÀÚ¸®
  • achromic point
    ¹«»öÁ¡(ÙíßäïÃ)
  • branch point
    ºÐÁöÁ¡(ÝÂò«ïÃ)
  • carbon dioxide compensation point
    ÀÌ»êȭź¼Ò º¸»óÁ¡(ì£ß«ûù÷©áÈÜÍßÁïÃ)
  • compensation point
    º¸»óÁ¡(ÜÍßÁïÃ)
  • critical point
    ÀÓ°èÁ¡ (×üÍ£ïÃ)
  • critical point drying
    ÀÓ°èÁ¡ °ÇÁ¶(×üÍ£ïÃËëðÏ)
  • crossover point
    ±³Â÷Á¡(Îßó©ïÃ)
  • end point
    Á¾¸»Á¡(ðûØÇïÇ)
  • end-point method
    Á¾¸»Á¡¹ý(ðûØÇïÇÛö)
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • equivalence point
    ´ç·®Á¡(Ó×ÕáïÇ)
  • extinction point
    ¼Ò¸êÁ¡(á¼ØþïÇ)
  • freezing-point osmometer
    ¾î´ÂÁ¡ »ïÅõ°è(ß¶÷âͪ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • alveolar cell carcinoma
    ÆóÆ÷¼¼Æ÷¾ÏÁ¾
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷±¸
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò, °ÇÀüÁö
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷
  • daughter cell
    µþ¼¼Æ÷, ³¶¼¼Æ÷
  • dendrite cell
    ³ª¹«°¡Áö¼¼Æ÷, ¼ö»ó¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diffuse large cell lymphoma
    ¹Ì¸¸¼º Å«¼¼Æ÷ÀÓÆÄÁ¾
  • ependymal cell
    ³ú½Ç¸· ¼¼Æ÷, »óÀǼ¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LCC lactose coliform count; left circumflex coronary (artery); left common carotid; left coronary cusp; ...
Tc cytotoxic T-cell; the generation time of a cell cycle; tricuspid closure
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
RFLPs Restriction Fragment Length Polymorphisms; Á¦ÇÑÈ¿¼Ò´ÜÆíÀå´ÙÇü
FR failure rate; film-screen radiograph; fasciculus retroflexus; febrile reaction; feedback regulation;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BCL Basic Cycle Length
CL Cycle Length
SCL Sinus Cycle Length
SSC Stretch-shortening cycle
C cycle
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • erythrocytic cycle
    ÀûÇ÷±¸ ¹ßÀ°È¯, Àû³» ¹ßÀ°È¯
  • hormonal cycle
    È£¸£¸ó ÁÖ±â
    È£¸£¸óÀÌ ¹Ýº¹Çؼ­ ºÐºñµÇ´Â ÀÏÁ¤ÇÑ ±â°£.
  • intranuclear cycle
    ÇÙ³» »ýȰ ȯ
  • life cycle
    »ýȰȯ, »ýȰ ÁÖ±â
    »ý¹°ÀÇ »ýȰ»ç¿¡ ÀÖ¾î ÀÏ·ÃÀÇ Çö»ó.
  • menstrual cycle
    ¿ù°æ ÁÖ±â
    ¿©¼º ¹× ÀϺΠ¿µÀå·ù ¾ÏÄÆÀÇ »ý½Ä±â Áß¿¡ ÀϾ´Â Àڱà ³»¸·ÀÇ ±ÔÄ¢ÀûÀÎ »ý¸®ÇÐÀû º¯È­À̸ç, Àڱà ³»¸·ÀÇ ÀϺΰ¡ Å»¶ôµÇ°í ÀϺÎÀÇ Ç÷¾×ÀÌ ÁúÀ» ÅëÇØ ¹èÃâµÈ´Ù.
  • menstural cycle
    ¿ù°æ ÁÖ±â
    ¿ù°æ ÁÖ±â´Â ¿ù°æ ÃâÇ÷ °³½Ã ù³¯ºÎÅÍ ´ÙÀ½ ¿ù°æ ÃâÇ÷ °³½Ã Àü³¯±îÁöÀÇ Àϼö¸¦ ¸»Çϸç, ¿ù°æ ÃâÇ÷ÀÌ ³¡³­ ÈÄ¿¡ ¼¼´Â °ÍÀº ¾Æ´Ï´Ù. Á¤»ó ÁÖ±â´Â 25~38ÀÏÀ̶ó°í »ý°¢ÇÏ¸é µÇ°í, ±âÃÊ Ã¼¿ÂÀÇ Àú¿Â»ó¿¡ ÇØ´çÇÏ´Â ¿©Æ÷±â
  • metabdic cycle
    ´ë»ç ÁÖ±â
  • mitotic cycle
    À¯»ç ºÐ¿­ ȯ
  • muscle pain cycle
    ±ÙÅëÁõ ÁÖ±â, ±Ùµ¿Åë ÁÖ±â
  • nitrogen cycle
    Áú¼Ò ¼øÈ¯
  • ovulation cycle
    ¹è¶õ ÁÖ±â
  • pulse cycle
    ¸Æ¹Ú ÁÖ±â
  • self-generating pain cycle
    µ¿ÅëÀ» À¯¹ßÇÏ´Â ÀÚ¹ßÀûÀÎ ¼øÈ¯ °úÁ¤
  • sulfur cycle
    Ȳ ¼øÈ¯
  • clear cell basal cell carcinoma
    Åõ¸í ¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
restriction nuclease <enzyme, molecular biology> Class of bacterial enzymes that cut DNA at specific sites. In bacteria their function is to destroy foreign DNA, such as that of bacteriophages (host DNA is specifically modified at these sites).
Type I restriction endonucleases occur as a complex with the methylase and a polypeptide that binds to the recognition site on DNA. They are often not very specific and cut at a remote site.
Type II restriction endonucleases are the classic experimental tools. They have very specific recognition and cutting sites. The recognition sites are short, 4-8 nucleotides and are usually palindromic sequences. Because both strands have the same sequence running in opposite directions the enzymes make double stranded breaks, which, if the site of cleavage is off centre, generates fragments with short single stranded tails, these can hybridise to the tails of other fragments and are called sticky ends.
They are generally named according to the bacterium from which they were isolated (first letter of genus name and the first two letters of the specific name). The bacterial strain is identified next and multiple enzymes are given Roman numerals. For example the two enzymes isolated from the R strain of E. Coli are designated Eco RI and Eco RII.
(10 Mar 1998)
restriction site A sequence in DNA that can be recognised and cut by a specific restriction enzyme.
(12 Dec 1998)
restriction-site polymorphism DNA polymorphism in which the sequence of one form of the polymorphism contains a recognition site for a particular endonuclease, but the sequence of the other form lacks such a site.
(05 Mar 2000)
MHC restriction <immunology> Restriction on interaction between cells of the immune system because of the requirement to recognise foreign antigen is association with MHC antigens (major histocompatibility antigens). Thus, cytotoxic T-cells will only kill virally infected cells that have the same Class I antigens as themselves, whereas helper T-cells respond to foreign antigen associated with Class II antigens.
(18 Nov 1997)
host restriction-modification A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it.
(09 Oct 1997)
DNA restriction enzymes <enzyme> Enzymes that are part of the restriction-modification systems. They catalyze the endonucleolytic cleavage of DNA sequences which lack the species-specific methylation pattern in the host cell's DNA. Cleavage yields random or specific double-stranded fragments with terminal 5'-phosphates. The function of restriction enzymes is to destroy any foreign DNA that invades the host cell. most have been studied in bacterial systems, but a few have been found in eukaryotic organisms. They are also used as tools for the systematic dissection and mapping of chromosomes, in the determination of base sequences of dnas, and have made it possible to splice and recombine genes from one organism into the genome of another.
Registry number: EC 3.1.21
(12 Dec 1998)
DNA restriction-modification enzymes Systems consisting of two enzymes, a modification methylase and a restriction endonuclease. They are closely related in their specificity and protect the DNA of a given bacterial species. The methylase adds methyl groups to adenine or cytosine residues in the same target sequence that constitutes the restriction enzyme binding site. The methylation renders the target site resistant to restriction, thereby protecting DNA against cleavage.
(12 Dec 1998)
ecori restriction enzyme <enzyme, molecular biology> A commonly-used restriction enzyme (enzyme which will cleave the phosphodiester bonds of DNA at specific nucleotide sequences) that came from the bacteria Escherichia coli and recognises the sequence GAATTC.
The enzyme will make a staggered cut of the double-stranded DNA molecule by cutting between the G and A on both strands.
(09 Oct 1997)
lactase restriction An inherited trait in which there is low lactase activity and thus there is defective lactose intestinal metabolism.
Compare: lactase persistence.
(05 Mar 2000)
anovulatory cycle A sexual cycle in which no ovum is discharged.
(05 Mar 2000)
Born-Haber cycle <physics> This is a mathematical description of the relationship between the electron affinity, heats of atomisation, ionisation energy and lattice energy of ionic compounds.
(09 Oct 1997)
bottoming cycle A cogeneration system in which steam is used first for process heat and then for electric power production.
(05 Dec 1998)
brain wave cycle The complete upward and downward excursion of a single wave, complex, or impulse as seen on an electroencephalogram.
(05 Mar 2000)
c3 cycle <biochemistry> The part of the photosynthesis process where carbon dioxide is converted into three-carbon compounds, which can then be turned into six-carbon sugars.
(07 Nov 1997)
c4 cycle <plant biology> An alternative, very efficient pathway used by plants living in areas with low levels of carbon dioxide, to convert carbon dioxide into a form usable by the plants during photosynthesis.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • estrous cycle
    (µ¿)¹ßÁ¤±â
  • family life cycle
    °¡Á· ÁÖ±â
  • food cycle
    ¸ÔÀ̼øÈ¯
  • fuel cycle
    (ÇÙÀÇ) ¿¬·á »çÀÌŬ
  • heliacal cycle
    ÅÂ¾ç ¼øÈ¯±â
  • nitrogen cycle
    Áú¼Ò ¼øÈ¯
  • product life cycle
    Á¦Ç°ÀÇ ¶óÀÌÇÁ »çÀÌŬ
  • solar cycle
    ÅÂ¾ç ¼øÈ¯±â;28 ÁÖ³â
  • trade cycle
    °æ±â ¼øÈ¯
  • cell
    ¼¼Æ÷
  • HeLa cell
    Èú·¯ ¼¼Æ÷(¿¬±¸¿ëÀ¸·Î ¹è¾çµÇ°í ÀÖ´Â ¾Ï¼¼Æ÷ÀÇ ÀÏÁ¾)
  • blood cell
    Ç÷±¸
  • brain cell
    ³ú½Å°æ¼¼Æ÷
  • cadmium cell
    Ä«µå¹Å ÀüÁö
  • cell
    ÀÛÀº¹æ;¾ÏÀÚ(¼öµµ¿ø ºÎ¼ÓÀÇ);»ç½Ç;¿ÀµÎ¸·Áý;¹«´ý;(±³µµ¼ÒÀÇ)µ¶¹æ;(¹úÁýÀÇ)±¸¸Û;²É°¡·çÁÖ¸Ó´Ï;ÀüÁö;¼¼Æ÷;(Á¶Á÷³»ÀÇ)ÀÛÀº °øµ¿;¼¼Æ÷(°ø»ê´ç µîÀÇ);°¡½ºÅë(±â±¸ÀÇ);ºñÆ®ÀÇ ±â¾ï¼ÒÀÚ;µ¶¹æ»ìÀÌÇÏ´Ù;ÀÛÀº ¹æ¿¡ Ʋ¾î¹ÚÈ÷´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á